quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·2d
PRRelease
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

FHTX· Foghorn Therapeutics Inc.
Health Care
Original source

Companies

  • FHTX
    Foghorn Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 17UpdateJefferies$12.00
  • Dec 18UpdateBTIG Research$11.00
  • Nov 7UpdateGuggenheim$12.00
  • Sep 17UpdateB. Riley Securities$10.00
  • Apr 23UpdateCitizens JMP$9.00
  • Jan 30UpdateB. Riley Securities$10.00

Related

  • SEC2d
    Foghorn Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • INSIDER10d
    SEC Form 4 filed by Gottschalk Adrian
  • PR15d
    Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
  • SEC28d
    SEC Form S-8 filed by Foghorn Therapeutics Inc.
  • SEC43d
    SEC Form 10-K filed by Foghorn Therapeutics Inc.
  • SEC43d
    Foghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR43d
    Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
  • INSIDER58d
    SEC Form 4 filed by Chief Financial Officer Maynard Ryan D
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022